April 22, 2018 11:14 AM ET


Company Overview of Oncimmune Holdings Plc

Company Overview

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody assay technologies to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT tests for liver and ovarian cancer. Oncimmune Holdings Plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Clinical Sciences Building

Nottingham City Hospital

Hucknall Road

Nottingham,  NG5 1PB

United Kingdom

Founded in 2015

47 Employees


44 1158 231 869


44 1158 231 958

Key Executives for Oncimmune Holdings Plc

CEO & Director
Total Annual Compensation: 200.0K GBP
CFO, Company Secretary & Executive Director
Age: 49
Total Annual Compensation: 97.0K GBP
Compensation as of Fiscal Year 2016.

Oncimmune Holdings Plc Key Developments

Oncimmune Holdings Plc Appoints Adam Hill as Chief Medical Officer and Chief Strategy Officer, Effective April 9, 2018

Oncimmune Holdings Plc announced the appointment of Dr. Adam Hill to the company's Board as Chief Medical Officer and Chief Strategy Officer, commencing on 9 April 2018. Most recently, Adam was Chief Medical Officer and later Chief Strategy Officer of McLaren Applied Technologies. Previously, he was Chief Medical Officer at Sectra AB.

Oncimmune Holdings plc Appoints Annalisa Jenkins as Independent Non-Executive Director

Oncimmune Holdings Plc appointed Annalisa Jenkins as Independent Non-Executive Director. Annalisa has approximately 25 years of experience in building and leading teams that advanced programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Her expertise in liver diseases and knowledge of companion diagnostics will prove invaluable, both at a Board level and strategically as continue to commercialise proprietary EarlyCDT® platform technology.

Oncimmune Holdings Plc Announces Unaudited Consolidated Earnings Results for the Half Year Ended November 30, 2017

Oncimmune Holdings Plc announced unaudited consolidated earnings results for the half year ended November 30, 2017. For the period, the company reported revenue of £77,000 against £114,000 a year ago. Operating loss was £2,822,000 against £2,438,000 a year ago. Loss on ordinary activities before taxation was £2,825,000 against £2,476,000 a year ago. Loss from continuing operations was £2,825,000 against £2,476,000 a year ago. Net loss attributable to owners of the parent was £3,036,000 against £2,322,000 a year ago. Basic and diluted loss per share was 5.7 pence against 4.5 pence a year ago. Net cash used in operating activities was £3,252,000 against £2,468,000 a year ago. Purchase of property, plant and equipment was £3,000 against £1,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

February 5, 2018

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oncimmune Holdings Plc, please visit www.oncimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.